Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 214-333-6 | CAS number: 1121-60-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 25 May - 16 June 1983
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP -guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 983
- Report date:
- 1983
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Version / remarks:
- adopted May 12, 1981
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- Pyridine-2-carbaldehyde
- EC Number:
- 214-333-6
- EC Name:
- Pyridine-2-carbaldehyde
- Cas Number:
- 1121-60-4
- Molecular formula:
- C6H5NO
- IUPAC Name:
- pyridine-2-carbaldehyde
- Test material form:
- other: liquid
- Details on test material:
- - Name of test material (as cited in study report): Pyridin-2-aldehyd
- Physical state: liquid
- Analytical purity: minimum 98% (GC)
- Lot/batch No.: no data
- Stability under test conditions: stable as pure test article , in water-solution stable for more than 2 hours
- Storage condition of test material: no data
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: outbred WISTARSTOCK , kfm: WIST (SPF Han.)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Kleintierfarm Madoerin AG , 4414 Fuellinsdorf , Switzerland
- Age at study initiation: males : 7 weeks , females : 8 weeks
- Weight at study initiation: males : 178-216 g , females : 164-190g
- Fasting period before study: 12-18 hours (overnight) before treatment , approximately 1 hour after treatment
- Housing: animals were caged in groups of five in Macrolon cages type 3 with wire mesh lids and standardized granulated soft wood bedding
- Diet (e.g. ad libitum): pelleted standard Kliba 343 , Batch 74/83 and 77/83 rat maintenance diet ad libitum
- Water (e.g. ad libitum): tap water , ad libitum
- Acclimation period: 1 week under test conditions
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 2
- Humidity (%): 55 +/- 10
- Air changes (per hr): no data
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Remarks:
- 2% solution of CMC in distilled water
- Details on oral exposure:
- VEHICLE
- Amount of vehicle (if gavage):
10ml at 400 mg/kg
10ml at 700 mg/kg
10ml at 1000 mg/kg - Doses:
- - 400 mg/kg
- 700 mg/kg
- 1000 mg/kg - No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing:
Mortality : Five times during the first day , daily thereafter
Body weight : Body weights were recorded on the day of administration and days 8 and 15 of the test
Symptoms : Five times at day 1 , daily thereafter for the nature , onset , severity and duration of all gross or visible toxic or pharmacologic effects or time of death
- Necropsy of survivors performed:
yes , all test animals were subjected to a complete gross necropsy . All animals surviving to termination were killed by exsanguination after pentobarbital anestesia . All organ abnormalities were recorded .
- Other examinations performed: other: The animals were checked daily for the symptoms listed below .
General behaviour : aggressive,crying,restlessness/excitement,nervousness,fear,sedation,somnolence,sleep,coma
Respiration : apnea,dyspnea
Eye : chromodacryorrhea,exophthalmos,miosis,mydriasis,whitish discharge,lid adhesion
Nose : rhinorrhea,epistaxis
Motility : akinesia,ataxia,drooped head,hyperkinesia,hypokinesia,paralysis flaccid,paralysis spatic,paddling movements,stiff movements,rolling movements,hunched posture
Body position : ventral body position,latero-abdominal position,curved body position
Skin : erythema,edema,necrosis
Motor susceptibility : spasms,tonic muscle spasms,clonic muscle spasms,opisthotonus,saltatory spasms,trismus,retching,"Straub" phenomenon,tremor,muscle -twitching
Various : loss of weight,emaciation,nagative corneal reflex,diarrhea,ruffled fur,necrosis of tissue of application area,salivation,pallor,cyanosis - Statistics:
- The LOGIT Model (COX , Analysis of Binary Data , London 1977) was applied to estimate the LD50 value . Additionally , the 90 , 95 and 99% confidence intervals for the LD50 for each sex and the slope of the concentration response line was estimated .
Results and discussion
Effect levelsopen allclose all
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 603 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- >= 407 - <= 773
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 566 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- >= 359 - <= 728
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 585 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- >= 463 - <= 686
- Mortality:
- Males :
Dose 400 mg/kg : no animal died
Dose 700 mg/kg : 1 animal died 5 h after application , 3 more animals died 24 h after application
Dose : 1000 mg/kg : 5 animals died 24 h after application
Females :
Dose 400 mg/kg : no animal died
Dose 700 mg/kg : 2 animals died 5 h after application , 3 more animals died 24 h after application
Dose : 1000 mg/kg : 5 animals died 24 h after application - Clinical signs:
- other: The following symptoms were observed : 400 mg/kg : sedation,dyspnea,chromodacryorrhea,rhinorrhea,ataxia,curved body position,loss of weight,ruffled fur 700 mg/kg : sedation,dyspnea,ataxia,curved body position,saltatory spasms,loss of weight,ruffled fur,cy
- Gross pathology:
- Mottled lungs were observed in seven killed rats of the 400 mg/kg group and in 9 rats which died in the 700 mg/kg group . In addition reddened colon was observed in 5 , and mottled liver in 2 rats of the 700 mg/kg group .
All rats of the 1000 mg/kg group showed mottled lungs as well as a reddened and mottled stomach and a reddened colon with red contents .
Applicant's summary and conclusion
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- The study was performed according to the OECD TG401 without deviations and therefore considered to be of the highest quality (reliability Klimisch 1). The validity criteria of the test system are fulfilled. The test material did induce mortality and treatment-related clinical signs in the dose group of 1000 mg/kg bw (100 % mortality) and in dose group 700 mg/kg bw (90 % mortality). In the dose group 400 mg/kg bw treatment-related clinical signs were observed too (0% mortality). The LD50 was identified to be 585 mg/kg bw for rats of both sexes with a 95% confidence interval of 463 – 686 mg/kg bw.
- Executive summary:
The acute oral toxicity of the test material was investigated in rats of both sexes. The test was conducted according to OECD TG401. As doses 400, 700 and 1000 mg/kg bw of the test substance were administered via gavage to the rats. Observations were made for a period of 14 days. The following symptoms were observed :
- 400 mg/kg bw : sedation, dyspnea, chromodacryorrhea, rhinorrhea, ataxia, curved body position, loss of weight, ruffled fur.
- 700 mg/kg bw : sedation, dyspnea, ataxia, curved body position, salutatory spasms, loss of weight, ruffled fur, cyanosis
- 1000 mg/kg bw : crying, ataxia, sedation, dyspnea, ventral-, abdominal and curved body position, spasms, salutatory spasms.
The above symptoms increased in intensity with higher dose levels.
All animals in the highest dose group died within 24 hours. In the 700 mg/kg bw dose group 3 animals died within 5 hours and another 6 within the following 24 hours. No animals died in the lowest dose group. The gross pathology performed after sacrifice reveals the following findings : Mottled lungs were observed in seven killed rats of the 400 mg/kg group and in 9 rats which died in the 700 mg/kg group . In addition reddened colon was observed in 5 , and mottled liver in 2 rats of the 700 mg/kg group . All rats of the 1000 mg/kg group showed mottled lungs as well as a reddened and mottled stomach and a reddened colon with red contents . An oral LD50 was identified to be 585 mg/kg bw for rats of both sexes with a 95% confidence interval of 463 – 686 mg/kg bw.
LD50 (males) : 603 mg/kg bw with a 95% Confidence interval of 407 - 773 mg/kg bw
LD50 (females) : 566 mg/kg bw with a 95% Confidence interval of 359 - 728 mg/kg bw
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.